Clinical Trial Update: ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating an ADAM17 inhibitor in combination with Rituximab after autologous stem cell transplant in diffuse large B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ADAM17 inhibitor (ADAM17 inhibitor)
• Rituximab (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Diffuse Large B Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-19